Cowley et al @sharoncowley01 Subclinical GCA in 17.5% with new PMR. Males with higher ESR more likely to have subclinical GCA. Subclinical GCA more axillary artery. Abstr#0747 #ACR23 #ACRbest @RheumNow https://t.co/CghmX1TKpf https://t.co/MJawtslLud

Phase 3 Study of IV Secukinumab for treatment of PsA - efficacious and safety profile similar to Subq version ~60% ACR 50 response maintained at week 52 2nd responses of MDA, PASI90, enthesitis, dactylitis resolution met @RheumNow #ACR23 Abs#0776 https://t.co/jikWd4fnGm

Entrevista de @RheumNow a las doctoras Griselda Serna Peña y Diana Flores Gutierrez sobre su trabajo de Screening y salud secual en pacientes con enfermedades reumáticas #ACR23 @SernaDra @ColMexReuma https://t.co/SyuFVXM9Sf

RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty

Reporting for @RheumNow! #ACR23 follow our coverage! @ACRheum @uptotate @Yuz6Yusof @ericdeinmd https://t.co/e4ShTzZhrE

• https://twitter.com/KDAO2011/status/1723818756466782389/photo/1

Upadacitinib on wearable device-measure activity SELECT-AXIS 2 Abs#0530 #ACR23 @RheumNow UPA had numerically higher mean daily step counts than PBO 11% improvement v PBO at wk 14 (diff of 345 steps/day) Sedentary pts: 22% improvement in daily step count from b/l on UPA (4% PBO) https://t.co/Gq91TmvfZC

What are effects of TNFi on Lipids in AxSpA? Ab#0531 #ACR23 @RheumNow 320 pts w AS - retrosp cohort, first-line TNFi, not on lipid Rx Chol and TG increase in 1st 3 mos of treatment. LDL & HDL: no signif change Inflam markers/Lipids correlated - suspect due to anti-inflamm effect https://t.co/qT5qUEOEvO

Is exercise safe in PsO/PsA? Ab0497 #ACR23 US of entheses before & after 60 min of badminton 🏸 7 PsA pts, 9 PsO pts, 196 US scans acquired. No signif change in VAS pain/tender entheses 4 pts w grade 1 doppler at 6 entheses, butnon-tender 1 pt w active PsA had worsening @RheumNow https://t.co/nsi9b6px0X

Translational implication/application of the #APOL1 story : Risk stratification, novel treatments, impact of tissue susceptibility to damage #ACR23 @RheumNow #DuboisLecture #SLE @ashira_md https://t.co/k23vFjeDeG

Ab#498 Does DMARD for PsO and PsA decrease MACE? #ACR23 @RheumNow Retrospective database Israeli study. PsO, PsA on MTX or bDMARD: lower MACE compared to health matched controled (HR 0.45-0.68, p<0.001) Pts on topical Rx had marginally Increased MACE (HR 1.14, p <0.001) https://t.co/0uRgjzYbFp

BKZ tx resulted in sustained improvements in pt‑reported pain and fatigue from Wk 16 - 52 in bDMARD-naïve and TNFi-IR pts w/ active PsA, w/ clinically meaningful improvements observed in >50% of pts in BE-OPTIMAL & BE-COMPLETE #ACR23 Abs 0527 https://t.co/AQKYUubKLl @rheumnow https://t.co/WsXlhENzL1